Published in JAMA on November 20, 2002
Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI (ISAR-REACT-3A) | NCT00735280
ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial | NCT00378612
Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort (INDUCE-it) | NCT01330589
75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2) | NCT00140465
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet (2014) 3.73
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation (2011) 2.63
The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke (2011) 2.35
Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ (2014) 2.21
Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ (2006) 1.91
P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest (2003) 1.90
Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov (2010) 1.66
Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol (2009) 1.55
Mean platelet volume and long-term mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol (2012) 1.49
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. J Stroke Cerebrovasc Dis (2012) 1.47
Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol (2013) 1.47
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int (2006) 1.47
Restrictive access to clopidogrel and mortality following coronary stent implantation. CMAJ (2008) 1.46
Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. Neurology (2010) 1.39
Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc (2009) 1.38
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties. J Orthop Traumatol (2013) 1.29
Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg (2012) 1.28
PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. J Biol Chem (2006) 1.27
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J (2014) 1.26
Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol (2012) 1.25
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. Stroke (2012) 1.23
Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol (2013) 1.23
Intracranial atherosclerosis: incidence, diagnosis and treatment. J Clin Neurol (2005) 1.16
Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J (2005) 1.15
Percutaneous coronary intervention: recommendations for good practice and training. Heart (2005) 1.14
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol (2010) 1.13
Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier. Proc Natl Acad Sci U S A (2016) 1.12
Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. J Geriatr Cardiol (2015) 1.10
Effect of gender difference on platelet reactivity. Neth Heart J (2011) 1.09
New antiplatelet agents for cardiovascular disease. CMAJ (2013) 1.09
Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J (2009) 1.07
Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol (2009) 1.03
Drug-eluting stents: new era and new concerns. Postgrad Med J (2004) 1.02
How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. Clin Res Cardiol (2008) 0.99
Significant increase in clopidogrel use across U.S. children's hospitals. Pediatr Cardiol (2010) 0.97
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol (2009) 0.97
Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc (2013) 0.97
Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation (2011) 0.96
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci (2010) 0.94
Clinical review: Traumatic brain injury in patients receiving antiplatelet medication. Crit Care (2012) 0.94
Percutaneous coronary intervention in the elderly. Nat Rev Cardiol (2010) 0.93
Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One (2013) 0.91
Personalized approaches to clopidogrel therapy: are we there yet? Stroke (2010) 0.90
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry. Am J Cardiol (2012) 0.90
Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol (2008) 0.90
Effect of addition of clopidogrel to aspirin on stroke incidence: Meta-analysis of randomized trials. Int J Stroke (2013) 0.90
Clopidogrel and percutaneous coronary interventions. JAMA (2003) 0.89
Cardiology. Br J Gen Pract (2004) 0.89
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Health Risk Manag (2012) 0.88
Clopidogrel and percutaneous coronary interventions. JAMA (2003) 0.88
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. Can J Cardiol (2009) 0.88
Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. Drug Healthc Patient Saf (2010) 0.88
Enterprise stent-assisted coiling of wide-necked intracranial aneurysms: clinical and angiographic follow-up. Interv Neuroradiol (2012) 0.88
Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? Neth Heart J (2011) 0.87
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation (2007) 0.87
PPARγ activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp Neurol (2013) 0.87
Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med (2010) 0.87
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol (2011) 0.87
Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc (2010) 0.87
Endovascular treatment of extracranial vertebral artery stenosis. World J Radiol (2012) 0.87
The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study. Korean J Intern Med (2010) 0.87
How to revascularize patients with diabetes mellitus: bypass or stents and drugs? Clin Res Cardiol (2006) 0.87
Diagnostic and Therapeutic Strategies for Acute Intracranial Atherosclerosis-related Occlusions. J Stroke (2017) 0.87
Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol (2011) 0.86
Discontinuation of anticoagulant or antiplatelet therapy for transrectal ultrasound-guided prostate biopsies: a single-center experience. Korean J Urol (2012) 0.86
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis (2009) 0.86
Trends in Ambulatory Prescribing of Antiplatelet Therapy among US Ischemic Stroke Patients: 2000-2007. Adv Pharmacol Sci (2012) 0.86
A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery--the APAP trial (ISRCTN45810007). Langenbecks Arch Surg (2011) 0.86
Clopidogrel in acute coronary syndrome: when, how much, how long? Z Kardiol (2005) 0.86
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. JACC Cardiovasc Interv (2013) 0.85
Antiplatelet therapy in populations at high risk of atherothrombosis. J Natl Med Assoc (2006) 0.84
Risk assessment and aspirin use in Asian and Western populations. Vasc Health Risk Manag (2010) 0.84
Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. Wien Med Wochenschr (2010) 0.84
Current strategies for ischemic stroke prevention: role of multimodal combination therapies. J Neurol (2007) 0.84
The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med (2010) 0.84
Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart (2015) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets (2009) 0.83
Current antiplatelet treatment strategy in patients with diabetes mellitus. Diabetes Metab J (2015) 0.83
Recent advances in the pharmacogenetics of clopidogrel. Hum Genet (2011) 0.83
Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord (2014) 0.83
Flow diversion in aneurysms trial: the design of the FIAT study. Interv Neuroradiol (2011) 0.83
Emerging antiplatelet agents, differential pharmacology, and clinical utility. J Blood Med (2010) 0.83
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clin Res Cardiol (2007) 0.83
Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. Surg Endosc (2011) 0.83
Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. World J Crit Care Med (2015) 0.82
Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction. Heart (2004) 0.82
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J (2014) 0.82
Temporal trends in the occurrence and outcomes of atrial fibrillation in patients with acute myocardial infarction (from the Atherosclerosis Risk in Communities Surveillance Study). Am J Cardiol (2014) 0.82
Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations. Pharmacoeconomics (2013) 0.81
Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Heart Vessels (2009) 0.81
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11
Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59
Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol (2009) 4.80
Can mobile health technologies transform health care? JAMA (2013) 4.75
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Pathway analysis of seven common diseases assessed by genome-wide association. Genomics (2008) 4.11
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science (2003) 3.34
Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv (2010) 3.24
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol (2003) 3.13
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med (2004) 3.07
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol (2004) 2.97
Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med (2012) 2.91
Arthritis medicines and cardiovascular events--"house of coxibs". JAMA (2004) 2.89
Accurate detection and genotyping of SNPs utilizing population sequencing data. Genome Res (2010) 2.84
Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J (2005) 2.80
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation (2004) 2.54
International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med (2011) 2.43
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol (2008) 2.38
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am J Hum Genet (2004) 2.36
Enrichment of sequencing targets from the human genome by solution hybridization. Genome Biol (2009) 2.32
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J (2004) 2.29
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA (2005) 2.26
The importance of phase information for human genomics. Nat Rev Genet (2011) 2.25
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke (2004) 2.24
Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet Med (2010) 2.23
Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). Circulation (2003) 2.21
Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation (2004) 2.21
The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol (2010) 2.19
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol (2003) 2.17
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA (2007) 2.10
Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med (2012) 2.09
Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov (2003) 2.06
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05
The genetics of health. Nat Genet (2006) 2.04
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol (2002) 2.03
Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med (2006) 2.02
Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics (2005) 2.01
A covering method for detecting genetic associations between rare variants and common phenotypes. PLoS Comput Biol (2010) 1.98
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA (2005) 1.94